Arcadia Biosciences(US:RKDA)2025-11-07 21:12Revenue and Income - Total revenues for the three months ended September 30, 2025, were $1,302,000, a decrease of 15.3% compared to $1,537,000 for the same period in 2024[4] - The net income attributable to common stockholders for the three months ended September 30, 2025, was $856,000, compared to a net loss of $1,612,000 for the same period in 2024[4] Cash and Assets - Cash and cash equivalents decreased to $1,120,000 as of September 30, 2025, from $4,242,000 at the end of 2024, representing a decline of 73.7%[2] - Total assets decreased to $8,584,000 as of September 30, 2025, down from $13,517,000 as of December 31, 2024, a reduction of 36.7%[2] Liabilities - Total liabilities decreased to $3,141,000 as of September 30, 2025, from $7,294,000 at the end of 2024, a decrease of 56.9%[2] Operating Expenses - Operating expenses for the three months ended September 30, 2025, were $2,454,000, down from $3,297,000 in the same period of 2024, a reduction of 25.6%[4] Cash Flow and Activities - The company reported a net cash used in operating activities of $3,878,000 for the nine months ended September 30, 2025, compared to $7,418,000 for the same period in 2024, indicating an improvement of 47.7%[6] - The company recognized a gain on the sale of intangible assets amounting to $750,000 during the nine months ended September 30, 2025[6] Research and Development - Research and development expenses were minimal at $9,000 for the nine months ended September 30, 2025, compared to $40,000 for the same period in 2024[4] Shares Information - The weighted-average number of shares used in per share calculations for basic shares was 1,367,192 for the three months ended September 30, 2025[4]